A phase IIa trial assessing BMB-101
Latest Information Update: 24 Sep 2021
Price :
$35 *
At a glance
- Drugs BMB-101 (Primary)
- Indications Dravet syndrome
- Focus Therapeutic Use
- Sponsors Bright Minds Biosciences
- 24 Sep 2021 New trial record
- 22 Sep 2021 According to Bright Minds Biosciences media release, this trial is targeted for 2H 2022